Cholangiocarcinoma in Patients with Crohn’s Disease

• 作者: Imad El-Hajj Isabella Reccia Tarek Debs Ziad El-Rassi
• 来源期刊: 癌症治疗(英文)
• 学科: 医学
• 关键词: CHOLANGIOCARCINOMA Crohn’s INFLAMMATORY BOWEL DISEASE INFLIXIMAB
• 年，卷（期）: 2015,（1）
• 页码范围: 21-24
• 页数: 4页
• 分类号: R5

摘要

Cholangiocarcinoma is an uncommon malignancy that increases with age. Cholangiocarcinoma has been linked to inflammatory bowel disease, and a relationship between inflammatory bowel disease, anti-tumour necrosis factor alpha antibody (Infliximab) and cholangiocarcinoma has been suggested. Although cholangiocarcinoma is usually associated with ulcerative colitis, recently more cases are being seen in association with Crohn’s disease. The risk of cancer in patients treated with Infliximab has been discussed, and whether Infliximab is associated with an increased risk of cholangiocarcinoma is not clear. Cholangiocarcinoma is an uncommon malignancy and it is difficult to establish a clear correlation with Infliximab treatment. A large number of reports are needed to further address these issues.